Tandem Diabetes Care Inc represents values of innovation, compassion, and excellence. Their corporate philosophy revolves around transforming the lives of people with diabetes through advanced technology and personalized care. As a leading medical device company, Tandem Diabetes Care focuses on delivering reliable and user-friendly insulin delivery systems. With a commitment to continuous improvement, they strive to create cutting-edge solutions that empower individuals to better manage their diabetes. Tandem Diabetes Care Inc's dedication to superiority in diabetes management is reflected in their dedication to research, product development, and collaborating with healthcare providers to provide high-quality and life-changing products for patients worldwide.

Tandem Diabetes Care Inc is primarily present in the United States.

Tandem Diabetes Care Inc has achieved several significant milestones. The company introduced its first automated insulin delivery system, the t:slim X2 Insulin Pump, which offers greater convenience and precision in diabetes management. Tandem also received the FDA approval for its t:slim X2 Insulin Pump with Control-IQ Technology, making it the first system to automate insulin delivery based on glucose levels. Additionally, Tandem Diabetes Care partnered with Dexcom to integrate their continuous glucose monitoring (CGM) technology with its insulin pumps, enabling real-time glucose readings and predictive alerts. These achievements reflect Tandem's commitment to innovation and improving the lives of individuals with diabetes.

Tandem Diabetes Care Inc is a renowned company specializing in diabetes management. Founded in 2006, Tandem Diabetes Care has emerged as a leading player in the healthcare industry. The company focuses on developing and providing advanced insulin delivery systems, revolutionizing the way individuals manage diabetes. Tandem Diabetes Care offers various user-friendly insulin pumps and related products to ensure better control and convenience for patients. With continuous innovation and commitment to improving the lives of people with diabetes, Tandem Diabetes Care has established itself as a trusted and reliable brand in the market.

The main competitors of Tandem Diabetes Care Inc in the market include Medtronic, Insulet Corporation, and Abbott Laboratories.

Tandem Diabetes Care Inc is primarily active in the medical device industry, specifically focused on the development and commercialization of insulin delivery systems for people with diabetes.

Tandem Diabetes Care Inc. is a medical device company specializing in the development, manufacturing, and marketing of innovative diabetes management systems. Their business model focuses on providing cutting-edge insulin delivery solutions, including insulin pumps and related accessories, to individuals with diabetes. Tandem Diabetes Care Inc. aims to enhance the quality of life for patients by offering user-friendly, advanced technologies that facilitate more effective diabetes management. With a strong emphasis on customer needs and technological advancements, Tandem Diabetes Care Inc. strives to improve insulin delivery and simplify diabetes management for patients worldwide.

Tandem Diabetes Care KGV ir -23,90.

Tandem Diabetes Care KUV ir 3,03.

AlleAktien kvalitātes vērtējums Tandem Diabetes Care ir 6/10.

gaidāmā Tandem Diabetes Care apgrozījums ir 908,62 milj. USD.

gaidāmā Tandem Diabetes Care peļņa ir -115,27 milj. USD.

Tandem Diabetes Care Inc is a company that specializes in the development and production of insulin pumps and related technologies for people with diabetes. The company's business model is based on providing innovative medical technologies to improve the treatment of diabetes. One of the main divisions of Tandem Diabetes Care Inc is insulin pump production. The company manufactures a variety of insulin pumps that allow for continuous insulin delivery. Tandem Diabetes Care Inc's insulin pumps are designed to accurately measure the body's insulin needs and minimize the risk of under or overdosing. They are also equipped with advanced features such as wireless data transmission or smartphone remote control. In addition to insulin pump production, Tandem Diabetes Care Inc also offers training and education programs to support patients in the use and maintenance of the devices. The company provides both online and offline courses to ensure that patients are always up to date and can effectively use their pumps. Another important division of Tandem Diabetes Care Inc is the offering of accessories and replacement parts for insulin pumps. The company provides a wide range of accessory products such as infusion sets, tubing, reservoirs, and filtering systems. These products support patients in effectively and safely operating their insulin pumps, leading to improved health outcomes. The provision of services is also an important component of Tandem Diabetes Care Inc's business model. The company offers various service offerings that contribute to improving patient satisfaction and treatment success. These include customer support to help with questions and issues, as well as automatic reordering of consumables to prevent patients from missing important parts of their insulin pump. In summary, Tandem Diabetes Care Inc offers a comprehensive portfolio of insulin pump products, accessories, and services to support the treatment of diabetes. The company is committed to continuously developing innovative technologies and products to improve patient health and enhance their quality of life. With a strong presence in North America and a growing presence in Europe and Asia, Tandem Diabetes Care Inc is dedicated to making diabetes treatment easier for patients worldwide.

Tandem Diabetes Care izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Tandem Diabetes Care vai uzņēmums nedod dividendes.

Tandem Diabetes Care ISIN ir US8753722037.

Tandem Diabetes Care WKN ir A2H5BX.

Tandem Diabetes Care simbols ir TNDM.

Pēdējo 12 mēnešu laikā Tandem Diabetes Care maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Tandem Diabetes Care plāno maksāt dividendes 0 USD apmērā.

Tandem Diabetes Care pašreizējā dividendu rentabilitāte ir .

Tandem Diabetes Care maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Tandem Diabetes Care pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Tandem Diabetes Care tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Tandem Diabetes Care apmērā 0 USD, kas tika izmaksāta 7.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.09.2024..

Pēdējās dividendes izmaksa notika 7.09.2024..

Gadā 2023, Tandem Diabetes Care izmaksāja 0 USD dividendes.

Tandem Diabetes Care dividendes tiek izmaksātas USD.